Increased levels of tumor infiltrating lymphocytes (TILs) could predict response to neoadjuvant chemotherapy in breast cancer [66, 67] and is also associated with better outcomes of ER-negative/HER2-negative cancers [68–71]. This evidence concerns the gene ERBB2 and breast carcinoma.